BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22963449)

  • 1. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
    Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
    BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
    Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
    Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
    Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.
    Molloy TJ; Bosma AJ; Baumbusch LO; Synnestvedt M; Borgen E; Russnes HG; Schlichting E; van't Veer LJ; Naume B
    Breast Cancer Res; 2011 Jun; 13(3):R61. PubMed ID: 21672237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
    Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
    Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
    Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
    Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
    Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
    Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun S; Pantel K; Müller P; Janni W; Hepp F; Kentenich CR; Gastroph S; Wischnik A; Dimpfl T; Kindermann G; Riethmüller G; Schlimok G
    N Engl J Med; 2000 Feb; 342(8):525-33. PubMed ID: 10684910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study.
    Solá M; Margelí M; Castellá E; Julian JF; Rull M; Gubern JM; Mariscal A; Barnadas A; Fraile M
    BMC Cancer; 2011 Jun; 11():252. PubMed ID: 21679400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
    Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
    Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.
    Mignot F; Loirat D; Dureau S; Bataillon G; Caly M; Vincent-Salomon A; Berger F; Fourquet A; Pierga JY; Kirova YM; Bidard FC
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):389-396. PubMed ID: 30291993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
    Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients.
    Hartkopf AD; Taran FA; Walter CB; Hahn M; Fehm T; Wallwiener M; Brucker SY
    Breast Cancer Res Treat; 2015 Jul; 152(1):51-55. PubMed ID: 26012646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
    Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
    Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
    Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.